secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001809519-24-000081
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx Q1 2024 revenue $197.9M; adjusted EBITDA $62.8M
------------------------------------------------------

- Revenue (GAAP and adjusted) of $197.9M; net loss $1.0M; adjusted net income $32.6M.
- Adjusted EBITDA $62.8M (31.7% margin); operating cash flow $42.6M.
- Exited Q1 with ~8 million consumers of prescription-related offerings.
- Interim CEO Scott Wagner cites progress and path to return to 'Rule of 40' company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000180951924000081/0001809519-24-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000180951924000081/gdrx-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001809519-24-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer